ClinicalTrials.gg
RecruitingNCT05202964OTABIOUpdated Oct 13, 2026

Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)

An observational study in Drug-Related Side Effects and Adverse Reactions and Treatment Adherence and Compliance, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · France.

Planned enrollment
18th of 21
60 · median 1,100
Started
2024
with 1 other
Observational
21 of 35
5 open now
Registered
30th of 35
by date
Lead sponsor
4 of 35
Hospices Civils de Lyon

Among the 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France, this one is the 18th largest by planned enrollment of the 21 observational ones that give a count, is one of 2 that started in 2024, is one of 21 observational ones, and was the 30th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

7 of the 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Drug-Related Side Effects and Adverse Reactions with a site in France, or all of them as a file.
02

Study summary

Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.

03

Conditions studied

  • Drug-Related Side Effects and Adverse Reactions
  • Treatment Adherence and Compliance

Keywords

  • Tolerance
  • Adherence
  • Antibiotic
  • BJI
  • adverse effect
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients having a BJI treated by at least one oral antibiotic after a surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years
  • Diagnosis of osteoarticular infection
  • Treatment with at least one oral antibiotic for a minimum expected duration ≥ 6 weeks with an expected end of treatment date
  • Patient who was informed and did not object to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Treatment for BJI with oral antibiotic without end of treatment date
  • treatment for BJI with parenteral antibiotic only
  • patient who doesn't have a telephone number or who doesn't want to give it
  • Adults subject to a legal protection measure
  • Pregnant or breastfeeding women
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Tolerance and adherence to oral antibiotics in patients managed for BJI

    Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery

    Other: Tolerance and adherence to oral antibiotics in patients managed for BJI

Interventions

  • OtherTolerance and adherence to oral antibiotics in patients managed for BJI

    Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire). Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3. Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.

06

What researchers measure

Primary outcomes

  1. Percentage of doses taken at 6 weeks

    Ratio of the number of doses taken over the theoretical number of doses to be taken over the period

    Time frame: At 6 weeks after surgery

  2. Percentage of doses taken at 3 months

    Ratio of the number of doses taken over the theoretical number of doses to be taken over the period

    Time frame: at 3 months after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Sep 2028, 51 months after the start.

Of 65 non-industry observational studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24. This study's planned 51 months is below that.

Counting every sponsor, half of 69 studies reached it within 45 months; a quarter within 24 and three quarters within 97.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Sep 2028 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartActual
Jun 13, 2024
Primary completionEst.
Sep 13, 2028was Sep 2026
CompletionEst.
Sep 13, 2028was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Sep 13, 2028
Oct 13, 2026
Study completion
Sep 2026→Sep 13, 2028
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hospices Civils de Lyon · Lyon, FranceContact person changed (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Sep 2026→Sep 13, 2028
    Study completion Sep 2026→Sep 13, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hospices Civils de Lyon · Lyon, FranceContact person changed (no phone or email listed)
    + 4 other changes: index terms, verification date, oversight details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05202964
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Jun 13, 2024
Primary completion
Sep 13, 2028 (estimated)
Completion
Sep 13, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Tristan FERRY, MD, PHD
Contact
tristan.ferry@chu-lyon.fr
4 26 73 29 38 ext. +33
Valérie MIRABET
principal investigator · Hospices Civils de Lyon

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion